| Bioactivity | Halopemide is a potent phospholipase D (PLD) inhibitor, with IC50s of 220 and 310 nM for human PLD1 and PLD2, respectively. Halopemid is a dopamine receptors antagonist, and acts a psychotropic agent[1][2]. | ||||||||||||
| Invitro | Halopemide (1-2 μM; 21 day) affects calcification in transdifferentiated MOVAS cells[3]. | ||||||||||||
| In Vivo | Halopemide (10 mg/kg; p.o.) induces dyskinesias in the majority of monkeys tested[2]. | ||||||||||||
| Name | Halopemide | ||||||||||||
| CAS | 59831-65-1 | ||||||||||||
| Formula | C21H22ClFN4O2 | ||||||||||||
| Molar Mass | 416.88 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Scott SA, et al. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol. 2009 Feb;5(2):108-17. [2]. Neale R, et al. Acute dyskinesias in monkeys elicited by halopemide, mezilamine and the "antidyskinetic" drugs, oxiperomide and tiapride. Psychopharmacology (Berl). 1981;75(3):254-7. [3]. Skafi N, et al. Phospholipase D: A new mediator during high phosphate-induced vascular calcification associated with chronic kidney disease. J Cell Physiol. 2019 Apr;234(4):4825-4839. |
Halopemide
CAS: 59831-65-1 F: C21H22ClFN4O2 W: 416.88
Halopemide is a potent phospholipase D (PLD) inhibitor, with IC50s of 220 and 310 nM for human PLD1 and PLD2, respective
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.